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Previous studies from this and other laboratories have shown that the novel microtubule
poison, JG-03-14, which binds to the colchicine binding site of tubulin, has the capacity
to promote both autophagy and apoptosis in breast tumor cells, as well as interfering with
endothelial cell function and potentially disrupting tumor vasculature. The current work
was designed to investigate the interaction between JG-03-14 and cell culture models of
colon carcinoma and melanoma, specifically HCT116 human colon carcinoma cells and
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B16F10 murine melanoma cells. In both cases, JG-03-14 promoted death in the bulk of
the treated population. FACS analysis, DAPI and TUNEL staining indicated that only a
small fraction of the cell population was undergoing apoptosis; furthermore, there was no
evidence of mitotic catastrophe (micronuclei in bi-nucleated cells). Staining with acridine
orange and monodansylcadaverine as well as electron microscopy demonstrated the
formation of autophagic vesicles, consistent with the cells undergoing extensive
autophagy. Cell cycle analysis indicated that cells had arrested in the G2/M stage, with
evidence of a hyperdiploid population. Residual surviving cells appeared to be in a state
of senescence; furthermore, the senescent cells failed to recover proliferative capacity,
indicating that the cells were reproductively dead. Toxicity studies in cardiomyocytes
with comparisons to combretastatin and taxol indicated that JG-03-14 was the less toxic
of the microtubule poisons. In summary, our studies indicate that JG-03-14 induces
autophagic and reproductive cell death in HCT116 colon carcinoma cells and B16F10
murine melanoma cells with limited toxicity to the normal cells that are generally
susceptible to taxol and combretastatin. The possibility of alternative mode(s) of cell
death (autophagy and irreversible senescence) induced by JG-03-14 makes it a potentially
useful candidate as a chemotherapeutic drug that could be used to treat cancers resistant
to apoptosis. The relative lack of toxicity of JG-03-14 provides additional support for its
potential use in the treatment of malignancies.
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CHAPTER 1 Introduction

I. Cancer
Cancer is the second leading cause of death worldwide and is expected to take
about 1500 lives per day this year (American Cancer Society, 2010). Two of the
more prominent sub-classes of cancer are colorectal cancer, which is the third
most prevalent cancer type, and melanoma. Colorectal cancer alone is projected
to generate 143,570 cases this year and is estimated to account for 51,370
deaths. In 2009, there were more than a million new cases of skin
cancer, including 68,720 cases of the most fatal form, malignant melanoma, with
8,650 deaths associated with melanoma alone (American Cancer Society, 2009).
For both of these cancers, if malignancies are detected early, the tumors
can be removed surgically, and the diseases are relatively curable. In contrast,
highly aggressive, metastatic lesions of colorectal cancer and melanoma are
notoriously resistant to chemotherapy (Fojo et al., 2007; Gray-Schopfer et al.,
2007; Gomez et al, 2000), and in cases where these tumors are not detected and
removed early in their progression, death is likely to result from the metastatic
lesion.
8

The development of therapies for both metastatic diseases is moving
forward quite slowly (Chin et al., 2006; Linos et al., 2009). Colorectal cancer is
usually treated with therapies that include 5-fluorouracil, monoclonal antibodies,
and inhibitors of EGFR and VEGF (Shia, 2008; Gallegos-Arreola et al, 2008;
Zrieki et al, 2008; Schwartz 2008; Igbal and Lenz 2004). Treatment options for
late stage melanoma are quite limited and include immunotherapies such as
Interleukin-2 and Interferon; however, these have been met with limited success
overall (Bajetta et al, 2002). Furthermore, the overall adverse effects of current
treatment strategies are quite debilitating and patient side effects such as
extreme flu-like symptoms and a host of organ toxicities which need to be closely
monitored (Hancock et al, 2004). In order to develop improved approaches for
treating these diseases, it is important to identify novel compounds that will be
effective at selectively targeting the tumor at pharmacological levels while
circumventing common mechanisms of resistance such as decreased
accumulation and drug inactivation in tumor cells, increased DNA repair and
mutation of drug targets (Eastman and Schulte, 1988; Lai et al, 1988; Cazin et al,
1992).

II. Metastasis and Angiogenesis
As with many cancers, malignant melanoma that has metastasized to distant
sites is very difficult to treat and is rarely curable (Hancock et al, 2004; Delaunoit
et al., 2005). Melanoma is not only highly metastatic in nature but also is
heterogeneous with regards to organ implantation (Kaplan et al., 2005). The
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lungs and liver are common organ sites for metastatic disease spread but all
organs are susceptible and late relapses are not uncommon (Tsoa et al, 1997).
Similarly, colorectal cancer is highly metastatic and most commonly targets
the liver. The distant organ lesions for colon cancers yield a 5-year survival rate
of only 11% (American Cancer Society, 2010).
The events that lead to the formation of these metastatic lesions may
present novel and previously unexplored targets for chemotherapy. It has been
found that tumors release tumor specific paracrine and autocrine factors that can
trigger bone marrow derived cells and hematopoetic progenitor cell release to
alter the micro-environment where the metastatic lesion may implant (Kaplan et
al, 2005). In the case of melanoma, this pre-metastatic niche and implantation
can occur in any organ, which makes the task of controlling the newly implanted
tumors particularly difficult. Cancer cells not only release factors for creating a
pre-metastatic niche in distant organs, but also release factors from the bone
marrow that will promote the recruitment of endothelial vessels for nutrient supply
(Bergers et al, 2003). One of the factors identified as being released by
melanoma under hypoxic conditions is vascular endothelial growth factor
(Shellman et al, 2003). VEGF is involved with the angiogenic switch which
occurs when the tumor is greater than 2 mm in diameter and no longer self
sufficient and requires the recruitment and formation of micro-vessels to siphon
nutrients from the host (Bergers et al, 2003). Cell division and migration of
endothelial cells for generating the tumor blood supply rely on microtubules for
function. This indicates that the subunits of microtubules could represent an
10

ideal target for tumoricidal and tumoristatic cancer chemotherapy, as well as
targets for anti-angiogenic prevention of disease recurrence (Pasquier et al.,
2008).

III. Microtubules as a Target for Chemotherapy
The cytoskeleton plays a dynamic and intricate role in cell survival and
proliferation (Nogales, 2001). Microtubules are a major component of the
cytoskeleton and function in transport, mitosis and cytokinesis. In current cancer
chemotherapy, a number of drugs target the microtubule subunits in order to
effectively disrupt proliferation (Jordan et al, 1998). The drug targets typically
bind and sequester the tubulin units, promoting polymerization or bind the
established microtubules and depolymerize them (Kuo et al., 2004).
Polymerization of microtubules by taxanes and other natural compounds such as
the epothilones can lead to arrest in the G2/M phase of the cell cycle followed by
apoptosis (Balog et al, 1996; Xiao et al, 2005; Wagenknecht et al, 1998; Blajeski
et al, 2001). The microtubule depolymerizing poisons include the vinca alkaloids
such as vincristine and vinblastine or the colchicine binding site agents
combretastatin A-4, colchicine and 2-methoxyestradiol. The end result of
exposure of tumor cells to many of these drugs is effectively an apoptotic
response through the induction of cell cycle arrest and effector caspase mediated
killing (Moss et al., 2006). However, there is growing recognition of other
responses to microtubule poisons including autophagy, aberrant mitosis and
senescence (Vicencio et al, 2008; Arthur et al 2007).
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IV. Cell Cycle Effects
Microtubule poisons that have been used as chemotherapeutic drugs act through
microtubule polymerization or depolymerization; these poisons can also activate
cell cycle checkpoints either during the G1 and S phases and/or during spindle
assembly. Taxol and other microtubule polymerizers interfere with spindle
dynamics and interfere with mitosis (Sudo et al, 2004; Desai, 1997). This spindle
disruption can lead to the activation of p53 (Amundson et al, 1998). The role of
p53 is complex; p53 will generally arrest cells in G1 through the cdk2-cyclin B
inhibitor p21/WAF1/Cip1. There is also evidence that p53 can induce various cell
killing pathways including autophagy and apoptosis (Levine et al, 2008; Shen et
al, 2001). G1 arrest though is not always permanent and cells can escape the
arrest, leading to chromosomal breakage in the subsequent G2 phase (Deckbar
et al, 2010). This subsequent chromosomal breakage and slippage may lead to
genomic instability and facilitate the development of resistance (Gisselsson,
2001).
Microtubule polymerizers and depolymerizers have strikingly different
effects on tubulin subunits but both effectively disrupt cell cycle transitions as
cancer therapy (Blajeski et al 2002). Depolymerizers similar to JG-03-14 have
been shown to arrest the cell cycle in the G2/M phase, as opposed to the G1
phase observed with many DNA damaging agents and radiation (Ivanov et al,
2007; Zhai et al, 1996; DiLeonardo et al, 2001). Along with the G2/M phase
12

arrest, some microtubule poisons, including JG-03-14, allow the cell to
continually replicate DNA without cytokinesis. This process is called
endoreduplication (Moon et al, 2008).
In our studies, we have observed that the G2/M arrest and subsequent
generation of a hyperdiploid population is accompanied by autophagic cell death
(Arthur et al, 2007). JG-03-14’s ability to permanently arrest cells in later stages
supports its potential use to promote cell killing and reproductive cell death. G1
arrest, which is commonly short-term arrest, has the potential to produce
resistant progeny through the cell re-entering the cell cycle and execution of
mitosis (Gisselsson, 2001). The absence of the necessity for apoptosis and
possibly the absence of p53 mediated G1 arrest are two potential benefits of
utilizing JG-03-14 as a microtubule de-polymerizering agent.

V. Death Responses

A. Apoptosis
The term apoptosis comes from the literal meaning of leaves falling from a tree.
Apoptosis is an evolutionarily conserved process where cell death is executed
through a family of cysteine-aspartic acid directed proteases knows as the
caspase family (Mignotte et al, 1998). In the death receptor extrinsic pathway
and intrinsic pathways, the mitochondria release cytochrome c, which is critical to
activate apoptotic factors such as Apaf-1 (Scoranno et al. 2003). Cytochrome-c is
released from the mitochondria when Bcl-2 family proteins Bax and Bad
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homodimerize and form a pore. This pore provides an escape route by which
mitochondrial cytochrome c can infiltrate the cytoplasm and form the apaf-1
complex moiety. This Apaf-1 moiety will then form a tetramer called an
apoptosome that is capable of cleaving caspase-9 (Twiddy et al, 2007).
Caspase-9 is an activator caspase that will cleave caspase-3, which
subsequently results in cleavage of poly-ADP ribose polymerase and ultimately
destruction of the cell. Apoptotic cell death is characterized by membrane
blebbing and the formation of apoptotic bodies, which is accompanied by
fragmentation of the nucleus and DNA (Taylor et al, 2008).
Although the apoptotic pathway has been well described, there is
mounting evidence that other mechanisms of death may be involved in the
response to cancer chemotherapy (Shao et al, 2004; Arthur et al, 2007). In many
cases the induction of apoptosis is in response to DNA damage and ultimately
leads to cell suicide dependent or independent of p53 (Gulbins et al, 2000).
However, tumor cells are notorious for evading apoptotic death through the
expression of anti-apoptotic proteins or other mutations (Weinberg, 2000). One
common mechanism for evasion of apoptosis is an increase in MDM2, a protein
that degrades p53, mutations in p53 or downregulation of p53 (Zhou et al, 2003;
Wattel et al, 1994). This is evidence that targeting other modes of cell death
would potentially be a useful strategy for cancer chemotherapy.

B. Autophagy
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There continues to be controversy in the scientific literature as to whether
autophagy is a mode of cell killing or a mode of survival or both. The term
autophagy comes from the Greek definition meaning “self eating”. The process
is thought to have a multitude of purposes and is activated in response to
hypoxic stress or nutrient deprivation (Azad et al, 2008). Nutrient deprivation
induced autophagy is thought to be under control of the PI3K-Akt-mTOR pathway
(Ravikumar et al, 2004). However, when nutrients are abundant in the presence
of chemotherapeutics, the mechanism of autophagic induction is somewhat of an
anomaly and yet to be fully described. Regardless, autophagy is initiated by the
formation of a double membrane vesicle called a phagophore. This double
membrane vesicle can then engulf various cell organelles, specifically damaged
mitochondria, peroxisomes or endoplasmic reticulum, forming the
autophagosome (Gozuacik and Kimichi, 2004). The autophagosome can then
fuse with the lysosome and digest the organelles to basic amino acids and
theoretically provide energy. This process is controversial because the recycling
of degraded products may be aiding in survival, or approach a critical threshold
and result in cell death (Alva et al, 2004).
This autophagic response has been observed in response to a growing
number of investigative chemotherapy agents. (Arthur et al, 2007; Cui et al,
2007). The development of resistance to apoptotic machinery and specifically
the general lack of sensitivity to chemotherapy of metastatic cancers contribute
to the potential utility of autophagic cell death (programmed cell death II) as a
target for novel chemotherapeutic agents. Metastatic disease is notoriously
15

resistant to common therapies and the possibility of exploiting autophagy as a
primary mechanism of cell killing could be beneficial.
After the initial disruption and cell killing, the cells may also be forced into
a state of reproductive death where they still metabolize but are no longer
replicating (Weaver et al, 2005; Vicencio et al., 2008). It has also been shown
that senescent cells release cytokines that can promote removal via the immune
system (Bartek et al., 2008; Xue et al., 2007). In a similar fashion, autophagic
cells may have a component to trigger activation and clearance by the innate
immune system (Thornburn et al., 2009).

C. Mitotic Catastrophe
Mitotic catastrophe has long been recognized as a mode of cell death, but
understanding the mechanisms that promote mitotic catastrophe has posed a
long-standing challenge (Castedo et al, 2004). The current understanding is that
mitotic catastrophe is cell death resulting from aberrant mitosis as a
consequence of deficient cell cycle checkpoints (Vakifahmetoglu et al., 2008).
The cells prematurely enter into mitosis and the attempt of the cellular
machinery to separate aberrant chromosomes may result in the formation of
micronuclei and nuclear fragments (Erenpreisa et al, 2001). Cells which undergo
mitotic catastrophe slip past cell cycle checkpoints leading to arrest in late stages
of cell cycle (Vakifahmetoglu et al, 2008). This study also mentions that mitotic
catastrophe may be a pre-stage for apoptosis. The JG-03-14 compound has not
been shown to promote the formation of micronuclei and the treated cells do not
16

appear to contain bifurcated nuclei (Arthur et al, 2007). This mechanism of cell
death remains ambiguous and requires further understanding before it can be
exploited in chemotherapeutic investigations.

VI. Senescence
The term replicative senescence refers to the inability of a cell to divide
indefinitely (Campisi et al., 2007). Most cancer cells have an enzyme called
telomerase that creates an extension of the telomeric DNA with each division and
allows for immortality and unlimited proliferation (Campisi, 1997). Studies have
also shown that cancer cells will respond to chemotherapy with a similar form of
reproductive death, termed accelerated senescence (Di et al, 2009). Accelerated
senescence can occur in response to DNA damage induced by radiation or
chemotherapy. A recent commentary described how, in response to
chemotherapeutic agents, cells can activate the ATM/ATR pathways which will
phosphorylate chk1/chk2 (Gewirtz et al., 2008). This phosphorylation will have
multiple downstream effects including the phosphorylation and activation of p53.
The phosphorylation of p53 has also been shown to activate p21, which can
inhibit cyclin dependent kinases. Cyclin dependent kinase inhibition leads to
activation of the Rb protein through dephosphorylation. This dephosphorylation
permits Rb to interact with E2F and promote this accelerated senescence (Di et
al, 2009; Gewirtz et al, 2008). This arrest theoretically will allow time for the cell
to repair DNA in to avoid passing the damaged DNA to daughter cells
(DiLeonardo, 1994). The induction of accelerated senescence and pathway
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description is with regards to DNA damaging agents such as topoisomerase
poisons and ionizing radiation (Di et al, 2009).
The JG-03-14 compound has been shown to induce senescence in p53 wild-type
MCF-7 cells but not the mutant p53 MDA-MB-231 (Arthur et al, 2007). This
senescent response appears to occur in the residual cells and not as the primary
mechanism of action. The growing intimacy between autophagy and senescence
may indicate that JG-03-14 induces autophagy and cells either die or enter into a
state of senescence (Arthur et al., 2007; Narita et al., 2009; Vicencio et al, 2008).
This may implicate autophagic cell death as a bridge in residual cells to undergo
senescence possibly through the generation of reactive oxygen species (Di et al,
2009). Adding to the intimacy between these pathways, the inhibition of
autophagy or sequestration of reactive oxygen species have been shown to
attenuate senescence and in some cases increase the amount of apoptotic cell
death (Young et al, 2010; Di et al, 2009).

VII.

The Conjugated Pyrrole, JG-03-14
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The compound currently under investigation is a di-brominated conjugated
pyrrole, which has shown cell-killing effects in multiple cell cancer cell lines
(Arthur et al, 2007; Mooberry et al, 2007; Nguyen, MS Thesis). Pyrroles are
components of more complex macrolides that contain multiple aromatic rings
(Juselius et al, 2000). These pyrrole compounds and analogs such as
imidazoles and lamellarins are widely being investigated as pre-clinical anticancer therapies (Bright et al, 2010; Iguchi et al, 2002; Baunbæk et al, 2008).
Early investigations have found that the JG-03-14 and its analogs bind to the
colchicine-binding site of tubulin and have depolymerizing effects on
microtubules (Mooberry et al, 2007). This latter study also demonstrated that
JG-03-14 has similar efficacy in competitive binding assays to Combretastatin A4 and [H-3] colchicine. JG-03-14 has also been shown to be effective at killing
MCF-7, MCF-7/E6, and MDA-MB-231 and 4T-1 metastatic breast tumor cells,
HCT-116 colon carcinoma cells, and B16F10 melanoma cells through both
autophagy and apoptosis possibly independent of p53/p21 induction (Arthur et al,
2007; Mooberry et al, 2007; this thesis). These cell lines include both p53 wild
type such as MCF-7 cell lines, HCT-116 cell line and B16F10 cell line. The
MDA-MB231 is of the p53 mutant genotype.
In addition to direct antitumor effects, JG-03-14 has been reported to
prevent, as well as disrupt existing endothelial vessel formation (Daylot-Herman
et al, 2009). The concentrations of JG-03-14 determined to inhibit endothelial
function were found to be sub-toxic in comparison to colchicines and nocadozole
which required concentrations high enough to induce apoptosis of the endothelial
19

cells (Daylot-Herman et al, 2009). Colchicine cannot be used clinically because
it is extremely toxic to patients and is also a substrate for the p-glycoprotein
pump (Druley et al, 2001; Mooberry et al, 2007). Our compound of interest, JG03-14, is not a substrate for the multi drug resistance P-glycoprotein pump, which
should be a decided advantage over other compounds of the same class
(Mooberry et al, 2007).
Considering the demonstrated need for effective therapies against
metastatic colon cancer and the high propensity for melanoma to metastasize,
we evaluated whether this compound would be effective against tumor cell lines
derived from these malignancies. Our aim with this series of studies was to
further enhance the understanding of the JG-03-14 compound with regards to
apoptosis, autophagy and senescence. To prove that autophagy is acting as a
primary mechanism of cell killing and show that apoptosis and senescence are
intimately linked to the process. Another goal was to expand on the effects of this
microtubule poison in a variety of cell lines and investigate the advantages of an
anti-angiogenic conjugated pyrrole as a potential chemotherapeutic drug.
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CHAPTER 2 Methods and Materials

Cell Culture HCT116 colon carcinoma cells were obtained from ATCC and kept
frozen in 10% DMSO (Sigma Chemical, St. Louis, MO) with Fetal Bovine Serum
(FBS) (GIBCO Life Technologies, Gaithersburg, MD) until use. HCT-116 cells
are quickly thawed and cultured in a T75 flask (Cellstar) in basal RPMI 1640
medium supplemented with 5% fetal bovine serum, 5% bovine calf serum, 2 mM
L-glutamine, and penicillin/streptomycin 0.5 ml/100 ml medium (10,000units/ml
penicillin and 10 mg/ml streptomycin, GIBCO Life Technologies, Gaithersburg,
MD) at 37° C under a humidified, 5% CO2 atmosphere. B16F10 murine
melanoma cells were generously provided by Dr. Kimber White from ATCC and
kept frozen and harvested the same as described for HCT-116. B16F10 cells
were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum,
2 mM L-glutamine, penicillin/streptomycin 0.5/100 mL (10,000 units/ml penicillin
and 10 mg/ml streptomycin), 1M HEPES and 7.5% NaBicarbonate (GIBCO Life
Technologies, Gaithersburg, MD and Sigma-Aldrich). H9c2 rat embryonic
cardiomyocytes were thawed and plated as described above. H9c2 cells were
maintained in culture with DMEM medium supplemented with 10% fetal bovine
serum, and streptomycin/penicillin as described above.
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All Cells were passaged at 80% confluency by washing one time with 1X
PBS(GIBCO) and harvested with trypsin-EDTA 0.25 %(GIBCO) then deactivated
with RPMI medium, collected and centrifuged at 15,000 rpm for 3 minutes.
Medium was aspirated and fresh media is added to the cell pellet; cells were
resuspended in media and 300 µL of the cell resuspension was placed into a
fresh T75 flask with 10mL RPMI medium. For all culture experiments, cells were
plated and permitted to adhere overnight before drug treatment.

Unless

otherwise indicated, all treatment involved continuous drug exposure.

MTT assay 5,000 cells in150µL media were plated in each well of a 96 well dish
and allowed to adhere overnight before drug treatment. After 48 hours, 100 µL of
the MTT solution ( 2mg/mL PBS prepared in the dark) was added to each well
and incubated for 3 hours at 37° C The MTT solution was removed, 100µL of
DMSO was added to each well, and the blue dye was allowed to dissolve for 5
minutes. An absorbance reading was taken at 490 nm (KC Junior software,
EL800 Universal Microplate Reader).

Time Course of Drug Effects on Viable Cell Number and Proliferative
Recovery Cells were plated at 1x106 cells per 96 mm Petri plate (CellStar) and
allowed to adhere overnight. At the various time points, the drug was aspirated
and cells were washed once using 1X PBS. Cells were then harvested and
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centrifuged at 15,000 rpm for 3 minutes and media was removed. The cell pellet
was resuspended in fresh media and 10µL of the cell resuspension was added
to 90µL of trypan blue exclusion dye (1:9; trypan blue: PBS). 10µL of the
mixture was placed onto a hemocytometer and viable cells (those that excluded
the dye) were counted in 4 separate quadrants (each quadrant containing 16
squares).

DAPI Staining Hoechst dye for Apoptosis and Mitotic Catastrophe At the
various time points, both adherent and non-adherent cells were harvested and
centrifuged at 15,000 rpm for 3 minutes. The media was aspirated and fresh
media was added to resuspend the pellet. Cell number was determined using
trypan blue exclusion. A dilution of 20,000 cells in 200 µL of 1X PBS per slide
were prepared and cells were spun at 10,000 rpm for 5 minutes (Shandon
Cytospin 4, Thermal Electron Corp). Slides were refrigerated until ready for
staining. Cells were fixed with 4% formaldehyde in PBS for 10 minutes at room
temperature, and then washed with PBS twice for 5 minutes at room
temperature. A 1:2 dilution of acetic acid and ethanol was used to fix the cells at
20° C for 5 minutes. The slides were then washed twice with PBS for 5 minutes
at room temperature. A 1:1000 dilution was prepared for Vectashield :Dapi and
each slide was mounted with 10µL of the solution. Coverslips were sealed using
clear nail polish and photographs were taken with a 10X objective lens using a
Nikon fluorescence microscope and an Olympus camera. Slides were stored at
4°C , and three fields per condition were evaluated.
23

Both adherent cells and supernatant were collected at various time points
and centrifuged at 1200 rpm for 5 min at 5°C. Cells were then resuspended in 5
mL of PBS and centrifuged again.

Supernatant from the centrifuge was

aspirated and cells were then resuspended in 0.075 M KCl by finger tapping and
allowed to incubate for 8 minutes at room temperature.

Cells were again

centrifuged and supernatent was aspirated. Cells were then fixed in the pellet
with a 3:1 ratio of methanol and glacial acetic acid.
dispersed on a slides moisturized with deionized water.

Samples were then
Slides were stored

overnight to dry. To stain the cells, Hoechst dye was diluted to 1:500 dilution of 1
mM Hoechst 33342 in nanopure water for 10 minutes at room temperature. The
slides were then rinsed once and sealed similar to slides for DAPI.

TUNEL staining for apoptosis
The method of Gavrieli et al. was utilized as an independent assessment of
apoptotic cell death in combined cytospins containing both adherent and nonadherant cells, as reported previously (Elmore et al., 2002; DeMasters et al.,
2006). Cells were fixed and fragmented DNA in cells undergoing apoptosis were
detected using the In Situ Cell Death Detection Kit (Roche), where strand breaks
are end labeled with fluorescein dUTP by the enzyme terminal transferase.

Flow Cytometry Cells were plated at 3x 106 million cells per 96 mm Petri plates
for each time point and allowed to adhere overnight. Setup was prepared for day
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5 and worked backward so that all treatments would complete on the same date.
Drug treatment was initiated the following day and drug was left on the cells for
continuous exposure. Upon the completion of treatment, media was aspirated
and cells were washed one time with 1X PBS. Cells were harvested using
trypsin and deactivated with 10ml media, then centrifuged at 15,000 rpm for 3
minutes. Media was aspirated and the cell pellet was resuspended in fresh
media. Cell numbers were determined using trypan blue exclusion dye. At least
1x10

6

cells per condition were used in the cell cycle analysis. 1.5 mL of

Propidium iodide stain with RNAse was added to each aliquot of 1x10

6

cells.

The cell suspension was filtered through a 70 micron mesh 2 times. All samples
were covered in aluminum foil and refrigerated until the next day.

FACs

acquisition was performed using the EPICS 753 flow cytometer (Coulter
Electronics, Hialeah, FL) using a 488 nm argon laser and standard optical
emission filters. A minimum of 13,000 events were collected per sample.
Cellular DNA distributions were analyzed at the various stages of the cell cycle
using Cytologic Software (Coulter Electronics).

Acridine Orange and Monodansylcadaverine staining for autophagy As a
marker for autophagy, the acridine orange staining method described by Paglin
et al, 2001 was used. Cells were plated at 2 x 105 per 6 well plate and allowed to
adhere overnight. Drug was added the following day and left on for continuous
exposure. At the final time point, the drug was removed and cells were washed
one time with 1X PBS. Cells were then stained with acridine orange (1ug/ml) for
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15 minutes. Monodansylcadaverine(MDC) is another marker for autophagy that
stains the autophagic membrane (Niemann et al, 2000).

MDC(Sigma) was

dissolved in DMSO and diluted to 0.1 mM. At selected time points, cells were
stained with 0.1 mM monodansylcadaverine for 10 minutes. The stain was
removed and cells were washed with 1X PBS four times before fresh media was
added to the wells. Pictures were taken with the inverted Nikon fluorescence
microscope and an Olympus camera with 20X objective lens.

Transfection with RFP-LC3 HCT-116 HCT-116 cells were prepared from frozen
stock and passaged twice at least 2 days before nucleofection. 1x106 cells were
centrifuged and suspended in a pellet.

100 µL of the Nucleofector V

(Nucleofector Kit V, Amaxa) mix was added to to resuspend the cells. The
resuspension was added to 1 µg of the RFP-LC3 vector and the entire
suspension was transferred to the cuvette. The cuvette was placed in the
Nucleofector device and program D-032 was used to transfect the cells. 500 µl
warm medium was added to the transfected solution and the total suspension
was transferred to a Petri plate. These steps were repeated for the positive and
negative controls using 2 µg of empty-GFP, and 2 µg pmax-RFP.

Stable

transfection was maintained using Gentimycin at 1µg/125 mL.

Electron Microscopy Cells were harvested from culture and 1x105 cells were
plated per plate on Permanox Petri dishes. Various drug treatments were
performed until endpoint. At each time point, cells were washed with 1X PBS
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and then fixed with 2% paraformaldehyde/2 % glutaraldehyde in 0.1M sodium
cacodylate buffer. After 1 hour at room temperature, fixative was removed and
replaced with 0.1M sodium cacodylate buffer, pH 7.4. Plates were then fixed in
1% osmium tetroxide in 0.1M-cacodylate buffer for one hour, after which they
were rinsed in 0.1M cacodylate buffer for 5-10 minutes. The plates were then
dehydrated in graded ethanol series: 50%, 70%, 80%, 95%; for 5-10 minutes
each. Then cell plates were dehydrated in 100% ethanol 3X, 10-15 minutes
each. This was followed by propylene oxide 3X, 10–15 minutes each. Cells
were then infiltrated with 50/50 mix of propylene oxide and PolyBed 812 resin
mix overnight. Next, the cells were infiltrated with pure PolyBed 812 resin
(Polysciences, Inc.) mix hours and overnight. The cells were placed in
embedding containing PolyBed 812 and placed in 60˚C oven overnight to
polymerize. Sectioning was done using Leica EM UC6i Ultramicrotome (Leica
Microsystems). Semi-thin sections for light microscopy (0.5µm – 1.0µm) were
collected on glass microscope slides and stained with 0.1% toluidine blue/0.1%
azure II/0.1% methylene blue in 1.0% sodium borate. For electron microscopy,
70-90 nm thick sections were collected on copper mesh grids and stained with
5% uranyl acetate and Reynold’s lead citrate. Images were taken using JEOL
JEM-1230 TEM (JEOL USA, Inc.) with the Gatan Ultrascan 4000 digital camera
(Gatan Inc, Pleasanton, CA).

Western Blotting After the indicated times, cellular proteins were extracted from
treated cells 1x106 using 100 to 200 µL of 1X Tris lysis buffer (1 M Tris(pH 6.8),
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10% SDS, and dH2O) containing protease inhibitors with boiling for 5 minutes.
Protein concentration was determined with a Lowry protein assay and 10 µg of
total cell lysates were separated using 12% SDS-PAGE.

Proteins were

transferred onto nitrocellulose membrane for 1 hour and blocked in TBS-Tween
20 buffer containing 5% nonfat dry milk. Membranes were then immunoblotted
with the respective primary antibodies overnight in 20°C. The following day, the
membrane was incubated with horseradish peroxidase-conjugated secondary
antibody

for

1

hour.

Signals

were

detected

using

an

enhanced

chemilluminescence detection reagents from Pierce (Rockford, IL).

Beta-galactosidase Staining for Senescence Senescence was determined
based on β-galactosidase staining in the HCT-116 after exposure to indicated
drug treatments. Cells were washed twice with PBS and fixed with 2%
formaldehyde, 0.2% glutaraldehyde for 5 min. The cells were washed again with
PBS and stained with a solution of 1 mg/mL 5-bromo-4-chloro-3-inolyl-βgalactosidase in dimethylformamide (20 mg/mL stock), 5 mM potassium
ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, 40 mM citric
acid/sodium phosphate, pH 6.0, and 2 mM MgCl2. Following overnight incubation
at 37 °C, the cells were washed twice with PBS and the images were capture for
visualization.

Clonogenic Survival Clonogenicity were determined with 72 hours of drug
treatment followed by washing of cells and replacement with fresh media. Plates
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were washed 1x with PBS prior to fixation with 100% methanol for 10 minutes.
After removal of methanol, plates were stained with crystal violet dye (1%) in
deionized water for 10 minutes. Colonies were based on visual staining. Vehicle
treated, JG-03-14 10nM and 100nM all received 500 cells while JG-03-14 250nM
and 500nM receive 2500 cells. Treatment groups were corrected for plating
efficiency.

DCF Staining for Reactive Oxygen Species
Cells were plated in 6-well plates at a density of 5x104 per well. After treatment
cells were incubated with 50 µM non-fluorescent DCF and intracellular reactive
oxygen species were visualized when di-acetate group are hydrolyzed to
fluorescent 2’, 7’dichlorofluorescein upon interaction with reactive oxygen
species. Images were taken using the same methodology as acridine orange and
MDC.

Statistical Analysis
Statistical analysis was performed using the Statview computer software.
ANOVA testing was performed and post-hoc analysis determined significance
base on a p-value of P<0.05.
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CHAPTER 3 Results

Part I. Effects of JG-03-14 on HCT-116 colon carcinoma cells

I. Growth inhibition of HCT-116 colon cancer cells by JG-03-14.

Initial studies evaluated the sensitivity of HCT-116 colon carcinoma cells to JG03-14 using the MTT dye assay (Mosmann, 1983). Cells were exposed to JG03-14 continuously for 48 hours prior to assessment of viable cell number. JG03-14 was ineffective at a concentration of 100nM, but produced > 50% growth
inhibition at 250nM, and > 70% inhibition at 500nM (Figure 1), findings similar to
what were reported previously in breast tumor cells (Arthur, 2007). All
subsequent studies were performed using JG-03-14 at a concentration of either
250nM or 500 nM. Sensitivity to Combretastatin A-4 was intended as a positive
control.
Cells were also assessed for clonogenic capacity after the initial 72 hours
treatment. Cell number was corrected for plating efficiency and calculated as a
percent of control. Table 1 indicates that treatments of HCT-116 cells with JG03-14 at concentrations of 250 nM and 500 nM showed loss of colony forming
capacity of 95% and 98%, respectively (Table I).
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II. Cell death induced by JG-03-14.

In order to distinguish between the effects of JG-03-14 on cell growth and on
overall viability, we monitored cell viability by trypan blue exclusion in cells
continuously exposed to JG-03-14 over a period of 5 days. Figure 2 shows a
time dependent decline in the number of viable HCT-116 cells upon continuous
exposure to JG-03-14 at 500nM, a concentration that was previously found to be
effective in promoting breast tumor growth arrest and cell death (Arthur, 2007).
The figure inset clearly demonstrates that the tumor cells exposed to JG-03-14
were dying, with approximately 95% of the HCT-116 cells lost after a period of 3
days.

III. Assessment of the mode of cell death
In previous studies, we have reported that JG-03-14 promotes primarily
autophagy in p53 wild type MCF-7 cells and both autophagy and apoptosis in
p53 mutant MDA-MB231 cells (Arthur, 2007). As HCT-116 cells are wild type in
p53, it was our expectation that cell death might also occur primarily via
autophagy. Nevertheless, we also examined the possibility of both apoptosis and
mitotic catastrophe in response to treatment with JG-03-14. Apoptosis was
assessed based on nuclear fragmentation by Hoechst, DAPI and TUNEL
staining. Autophagy was evaluated based on acridine orange and
monodansylcadaverine staining, electron microscopy as well as redistribution of
RFP-LC3 and autophagic flux using p62. Mitotic catastrophe was based on the
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formation of bi-nucleated cells with micronuclei (DeMasters et al, 2006). Figure 3
shows the untreated vehicle control with a clearly defined intact nucleus. With a
few isolated exceptions, the nuclei of cells treated with JG-03-14 were intact
although significantly enlarged in comparison to control cells, with little evidence
for either apoptosis (Figure 3A) or mitotic catastrophe using a higher
magnification with Hoechst (Figure 3B). The absence of apoptosis was also
confirmed by absence of TUNEL positive staining (Figure 7C) and supported by
FACS analyses performed previously by Tuyen Nguyen (MS Thesis, 2008). In
contrast, taxol promoted extensive nuclear fragmentation, indicative of apoptosis
while combretastatin treatment resulted in mitotic catastrophe (Bartek & Lukas,
2001).
Previous work by Ms. Nguyen also indicates that JG-03-14 transiently
arrested 66.4% of the HCT-116 p53 wild type tumor cells in the G2/M cell phase
after the first day of treatment. This G2/M block persisted for at least 72 hours.
After 72 hours, the cell cycle distribution shifted, with 63% of the cells in G2/M
and 4.5% in G1, with a very small sub G1 population. Of particular interest was
the observation that these p53 wild type cells appear to continue to replicate their
DNA following the G2/M arrest, resulting in a hyper diploid population. This
effect was observed after the first day of treatment and the hyper diploid cell
population had more than doubled after 72 hours. In contrast, Taxol arrested
41.72% of cells in the G1/G0 phase after just 24 hours, and this cell cycle
distribution grew to 59.76% after 72 hours.
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In summary, only a small fraction of the cell population could be detected
in the sub G1 phase both at 24 and 72 hours following the initiation of treatment
with 500 nM JG-03-14, confirming that apoptosis likely plays only a minor role in
cell death induced by JG-03-14 in the HCT-116 cells.
In contrast to the relative lack of apoptosis, there was extensive evidence
of autophagy after treatment with JG-03-14 in the HCT-116 cells. Figure 4A
shows that control HCT-116 controls stained with acridine orange had a single
large vesicle that was situated near the nucleus; in contrast, extensive punctuate
distribution of small acidic vesicles within the cytoplasm, indicative of autophagy,
was observed in cells treated with JG-03-14. The cells treated with JG-03-14
were also quite enlarged, nearly double the size of the untreated cells.
Utilizing monodansylcadaverine, a stain that binds to the lipid membrane
of the autophagosomes, results in similar patterns to what was observed with the
acridine orange staining. Specifically, as shown in figure 4B, the controls show a
single vacuole closely associated with the cell nucleus while the cells treated with
JG-03-14 show a highly distributed punctuate pattern throughout the cytoplasm.

LC3-II is a cleaved product of LC3-I and is involved in the formation of
autophagosomes (Kabeya et al, 2000). We further monitored the distribution
of LC-3 II in the treated cells. HCT-116 colon tumor cells were transfected with
an RFP-LC3 vector via nucleofection and the cells were observed under
fluorescence after 72 hours of exposure to 500 nM JG-03-14. After 72 hours of
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drug treatment, the transfected cells showed a punctuate distribution of LC-3 II
proteins in the cytoplasm, again consistent with the promotion of autophagy
(Figure 5A).
In order to further confirm autophagic flux, we monitored p62 protein
expression.
formation.

This is a scaffold protein associated with autophagic membrane
The flux and degradation of p62 indicates that the autophagic

machinery is in effect degrading the membrane to completion (Bjørkøy et al,
2009).

In HCT-116 cells treated with 500 nM JG-03-14 for 48 hours, we

observed a clear reduction in p62 protein expression. This reduction was also
inhibited with a late stage autophagic inhibitor, Chloroquine (Figure 5C).
Starvation was included as a positive control for degradation of p62.
Another method to visualize autophagic vesicle formation is the use of
electron microscopy imaging (Ylä-Anttila, et al., 2009). This is a gold standard
for vesicle formation. The image in figure 5B clearly shows the induction of
autophagic vesicles after 72 hours of treatment with 500 nM JG-03-14.

IV. Effect of autophagic inhibition on JG-03-14 induced cyto toxicity
The role of autophagy is still undefined and appears to have a role in both
cell protection and cell killing. In efforts to confirm that JG-03-14 is killing the
HCT-116 cells through autophagic processes, studies assessed the impact of
inhibition of autophagy on tumor cell sensitivity to JG-03-14. As shown in figure
6A, the concurrent treatment of cells with JG-03-14 and chloroquine was only
slightly protective. Chloroquine is a lysomotropic inhibitor, which merely
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maintains pH and prevents acidification of autophagic vesicles, only preventing
the last step of autophagy (Shintani et al., 2001). In figure 6B, it is clear that
chloroquine produces a blockade to autophagy, as shown by condensed
fluorescent staining. More quantitative evidence that chloroquine blocks
autophagic flux is provided by figure 5B, which shows that concurrent treatment
with JG-03-14 and chloroquine protected p62 from degradation.
The fact that inhibition of autophagy did not provide complete protection to
the cells suggested that a blockade to autophagy was likely to be leading to an
alternative mode of cell death, specifically apoptosis. Figure 6C clearly shows a
large increase in TUNEL positive staining for concurrent treatment with JG-03-14
and chloroquine. Combretastatin A-4 is utilized as a positive control for induction
of apoptosis.

V. Promotion of senescence and lack of proliferative recovery in residual
surviving cells
In previous studies, we have reported that residual cells that appear to have
survived the drug treatment were in a state of senescence arrest (Arthur, 2007);
in some reports, senescence has been succeeded by proliferative recovery
(Sliwinska, 2009; Elmore et al., 2005). In the current studies, we observed that
the residual cell population that survives the initial cytotoxic effects of JG-03-14 is
arrested in state of senescence, based on beta-galactosidase staining as well as
cell enlargement and spreading (Figure 7A). Three days post treatment, nearly
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100% of the residual surviving population stained positively for beta
galactosidase (Figure 7B).
Although senescence is generally thought to be irreversible, we have observed
recovery of proliferative capacity in breast tumor cells subsequent to treatment
with either doxorubicin or radiation (Sliwinska, 2009; DeMasters, 2004; Jones et
al., 2005). In order to determine whether the cells exposed to JG-03-14 had lost
self-renewal capacity, drug was removed after 3 days, and cell number was
followed for an additional 17 days. However, we failed to detect any evidence of
re-growth, indicating that the cells had apparently lost all reproductive capacity
(Figure 7C).

VI. Reactive Oxygen Generation as Possible Role in Toxicity
The studies in Figure 8 compared reactive oxygen generation by JG-0314, taxol, and combretastatin by DCF staining generated significantly less
reactive oxygen after 72 hours than the other compounds (Figure 8).

This

reactive oxygen generation likely contributes to the toxicity generated by these
clinical therapeutic agents, specifically cardiotoxicity and peripheral neuropathy
(Kim et al, 2004).
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Table 1 – Clonogenic Survival following exposure with JG-03-14 (% control)
250 nM
500 nM
4.65 ± 0.07*
1.65 ± 0.25*
Values represent average colonies formed 2 weeks post 72 hours treatment with
JG-03-14
* P= <0.0001 compared to Control group
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Figure 1. Sensitivity to JG-03-14 in HCT-116 cells. Cells were exposed to JG03-14 at the indicated concentrations for 48 hours and cell number was evaluated
using the MTT dye assay. Values shown are from a representative experiment
with quadruplicate samples for each condition. Studies were reproduced in 3
additional replicate experiments. Error bars reflect standard deviations and
significant differences from DMSO treatment are indicated by * (P<0.05), which
were assessed by the ANOVA and Tukey/Kramer post-hoc analysis.

38

80

70
JG0314 (500nM)

9
8

60

7
6

Viable Cell Number (x10^4)

5
4

50

3
2
1
0
Day 0

Day 1

Day 3

Day 5

40

30

20

10

0

Day 0

*

*

*

Day 1

Day 3

Day 5

Figure 2. Time dependent loss in cell viability by exposure to JG-03-14. HCT-116
cells were either continuously exposed to DMSO or 500nM JG-03-14 and viable cell
number was monitored by trypan blue exclusion over a period of 5 days. Values shown
are from a representative experiment with triplicate samples for each condition. Studies
were reproduced in 3 additional replicate experiments. The inset shows the decline in
viable cell number using an expanded Y-axis. Significance differences from DMSO
treatment are indicated by * ( P<0.05) and were assessed by ANOVA and Fisher’s PLSD
post-hoc analysis.
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A.
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JG-03-14

Taxol

JG-03-14

Combretastatin A-4

B.
DMSO

Figure 3. Images of HCT-116 cells exposed to JG-03-14. HCT-116 cells were
treated with 500nM JG-03-14 for 72 hours. Apoptosis (nuclear fragmentation) and
mitotic catastrophe (bi-nucleated cells with micronuclei) were evaluated based on
morphology by DAPI (A) and Hoechst dye (B) staining, respectively. Magnifications
shown are 200X and 400X, respectively.
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Figure 4. Staining for autophagy in HCT-116 cells exposed to JG-03-14. HCT-116
cells were treated with 500nM JG-03-14 continuously and autophagy was assessed
based on acridine orange staining ( A) and monodansylcadaverine staining (B) at 48
and 72 hr. Magnifications shown are 200X.
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Figure 5. Confirmation of autophagy by JG-03-14 in HCT-116 cells. HCT-116
cells were treated with 500nM JG-03-14 continuously and autophagy was
assessed based on redistribution of RFP-LC3 (A) and electron microscopy (B) at
48 and 72 hr. Magnifications shown as 200X for RFP, and a representative scalebar for EM. Autophagic flux (C) was assessed based on the degradation of p62
and all treatments were performed for 48 hours. Chloroquine was used either
independently or concurrently at 10 µM.
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Figure 6. Influence of chloroquine on sensitivity to JG-03-14. HCT-116 cells
were continuously exposed to 500 nM JG-03-14, 10 µM Chloroquine, or the
combination treatment for the indicated times. Trypan blue was utilized for measure
of cell viability (A), autophagy was visualized by MDC (B), and both adherent and
non-adherent cells were collected for the TUNEL assay to measure apoptosis (C).
Values shown are from a representative experiment with triplicate samples for each
condition. Studies were reproduced in two additional replicate experiments.
Significance differences from DMSO treatment are indicated by * (P<0.05) and were
assessed by the two-way ANOVA and Fisher’s PLSD post-hoc.
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Figure 7. Induction of senescence and lack of proliferative recovery in HCT116 cells treated with JG-03-14. HCT-116 cells were treated with 500nM JG-0314 for 72 hours, drug was removed and replaced with drug free medium.
Medium was replaced every 3 days. A. Senescence in residual surviving cells by
beta-galactosidase staining. B. Three representative fields were quantified and
counted as postive or negative for beta-galactosidase staining. C. Viable cell
number. Significance differences from DMSO treatment day 3 are indicated by *
(P<0.05) and were assessed by the two-way ANOVA and Fisher’s PLSD posthoc.
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Figure 8. DCF stain Assessment of Induction of Reactive Oxygen Species.
HCT-116 cells were continuously exposed to 500 nM JG-03-14, 100 nM taxol
and 100 nM combretastatin A-4. Residual cells were stained using DCF
fluorescent stain and images were taken at 400x magnification.
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Results B. Effects of JG-03-14 in B16F10 melanoma cells

I. Effects of JG-03-14 on viability of B16F10 murine melanoma cells.

In an effort to extend the utility of the JG-03-14 compound to additional
tumor models; studies of drug action were performed in B16F10 murine
melanoma cells. Figure 9 indicates that JG-03-14 produced a concentrationdependent reduction in clonogenic survival, with substantial effects evident at
concentrations of 250 and 500nM, similar to what was reported previously in
breast tumor cells (Arthur, 2007).
Table II indicates that there was a reduction of 96% and 97% when
B16F10 cells were exposed for 72 hours to 250 nM and 500 nM JG-03-14,
respectively.

All subsequent studies were performed using JG-03-14 at

concentrations of either 250 nM or 500 nM (Table II).

II. Cell death induced by JG-03-14.

The previous clonogenic survival assay indicates a single cells ability to
form a colony with exposure to JG-03-14. Therefore, we also monitored the
effects of JG-03-14 on cell viability over a period of 5 days by simple trypan blue
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exclusion. Figure 10 shows a time dependent decline in viable cell number when
B16F10 cells were treated by continuous exposure to JG-03-14 at 500nM, a
concentration that was previously found to be effective in promoting growth arrest
and cell death in breast tumor cells (Arthur, 2007). The figure inset clearly
demonstrate that the tumor cells exposed to JG-03-14 were dying as early as
day 3, and that approximately 55% of the melanoma cells were lost after a period
of 3 days.

III. Assessment of apoptosis
In previous studies, we have reported that JG-03-14 promotes primarily
autophagy in p53 wild type MCF-7 cells and both autophagy and apoptosis in
p53 mutant MDA-MB231 cells. As B16F10 melanoma cells are wild type in p53, it
was our expectation that autophagic cell death would also be the primary mode
of cell death. However, in order to examine the possibility that the cell death
observed in B16F10 melanoma cells might be due to apoptosis, nuclear
morphology was evaluated by DAPI staining. Figure 11A shows the untreated
vehicle control with a clearly defined intact nucleus. With a few isolated
exceptions, the nuclei of cells treated with JG-03-14 were intact although
significantly enlarged in comparison to control cells. These cells also did not
present evidence of mitotic catastrophe, where bifurcated cells have micronuclei
resulting from aberrant mitosis (Figure 11B).
We also assessed the effects of other microtubule poisons (taxol, and
combretastatin A-4, both at 100 nM) based on other publications and utilized
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these poisons as positive controls for apoptosis. DAPI staining showed that the
majority of nuclei were fragmented by taxol treatment after three days (Figure
11A). Combretastatin treatment appeared to promote mitotic catastrophe (Figure
11B). Consequently, the actions of JG-03-14 in terms of promoting cell death
appear to differ markedly from that of these other microtubule poisons. Although
some apoptotic bodies were detected in response to JG-03-14, the percentage
was minimal and in no way could account for the amount of cell death seen
following treatment.
In order to further understand the effects of JG-03-14 on B16F10, we used
propidium iodide staining and single cell flow cytometry to quantify the cell cycle
alterations induced by this novel microtubule poison.

IV. Cell cycle effects of JG-03-14

The next series of experiments was designed to verify the absence of
apoptosis based on the detection of a cell population with DNA content lower
than 2N, indicative of the DNA fragmentation that is a hallmark of apoptosis.
FACS analysis confirmed that only a small fraction of the cell population could be
detected in the sub G1 phase both at 24 and 72 hours following the initiation of
treatment with 500 nM JG-03-14 (Figure 12). Again, using treatment with taxol
and combretastatin as positive controls, we detected substantial populations of
sub G1 cells after treatment with these microtubule poisons. These studies
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confirm that apoptosis likely played only a minor role in cell death induced by
JG-03-14 in the B16F10 melanoma cell line.
Figure 4 also presents an analysis of cell cycle distribution of B16F10 cells
treated with JG-03-14. JG-03-14 transiently arrested the p53 wild type tumor
cells in the G2/M cell phase after the first day of treatment, and this G2/M block
persisted for at least 72 hours. After 72 hours, the cell cycle distribution shifted,
with 38.9% of the cells in G2/M and 14.7% in G1/S. Of particular interest was the
observation that these p53 wild type cells appear to continue to replicate their
DNA following the G2/M arrest, resulting in a hyperdiploid population. This effect
was observed after the first day of treatment and the hyper diploid cell population
had more than doubled after 72 hours, where 29.7% of the B16F10 cells were
polyploid.
As indicated above, FACS analysis determined that after 24 hours a very
large population is in G2/M arrest. However, after 72 hours there is a small
population of cells that are sub-G1. This percent population does not correlate
with the extent of cell death observed. This apparent apoptosis independent cell
death indicated that it was important to assess alternative pathways for cell killing
such as mitotic catastrophe and autophagy.

V. Assessment of mitotic catastrophe in B16F10 melanoma cells after JG03-14 treatment
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Since apoptosis could only account for a small fraction of the cell death
observed in the B16F10 melanoma cells upon treatment with JG-03-14, it
appeared likely that other modes of cell death such as mitotic catastrophe or
autophagy might be responsible for the time dependent decline in cell number
observed in the studies presented in Figure 10. Due to the presence of enlarged
cells and a hyper-diploid cell population we considered the possibility of mitotic
catastrophe being the mode of cell death in B16F10 cells. However as shown in
figure 11B, analysis using Hoechst stained cells failed to detect evidence of binucleated cells and micronuclei that are characteristics of mitotic death
(DeMasters et al, 2006)

VI. Induction of autophagy by JG-03-14.

In our previous work, the p53 wild type MCF-7 and p53 mutant MDA-MB231 breast tumor cells demonstrated essentially similar sensitivity to JG-03-14;
however, their response was different with regard to the modes of cell death. As
in the current studies, MCF-7 cells were not dying through apoptosis based on
FACS analysis and the TUNEL assay, but rather through autophagy while the
p53 mutant MDA-MB231 cells demonstrated both apoptosis and autophagy.
Consequently, we assessed the promotion of autophagy by JG-03-14 using a
number of assays including acridine orange and monodansylcadaverine staining,
and electron microscopy.
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Figure 13A shows a quite extensive level of basal autophagy in the
B16F10 melanoma cells based on the mosaic distribution in control cells, which
is consistent with a recent time-lapse GFP-LC3 by Tormo et al., (2009).
However, treatment with JG-03-14 resulted in an increase in puncta formation
throughout the cell, consistent with the formation of acidic vesicles.
To confirm the promotion of autophagy, we used an additional approach,
staining of autophagic vesicles with monodansylcadaverine, a stain that binds to
the lipid membrane of the autophagosomes (Niemann et al., 2001). Figure 13B
shows a similar pattern to what was observed with the acridine orange staining.
Specifically, the controls show a more condensed pattern of vacuoles while the
cells treated with JG-03-14 show a highly distributed punctuate pattern
throughout the cytoplasm. The cells treated with other microtubule poisons did
not show enhanced formation of autophagic vesicles (Figure 13A and 13B).

Another mechanism for detection of autophagic vesicles is the use of
electron microscopy (Figure 14). Here we show that the control cells there are
clearly intact mitochondria and a healthy nucleus. The B16F10 cells that have
been treated with JG-03-14 (500 nM) show clear nuclear and cell enlargement as
well as induction of autophagic vesicles that commence degradation of damaged
cellular constituents.

VIII. Effects of autophagic inhibitors on the response to JG-03-14 treatment
in B16F10 cells
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There is continuing controversy in the literature as to whether autophagy
is a cytoprotective mechanism or an actual mode of cell death (Mori et al, 2007;
Boya et al, 2005). In a further attempt to confirm the mode of cell death caused
by JG-03-14 and to elucidate the ambiguous role of autophagy, we sought to
block autophagy. In efforts to address this question, cells were pre-treated or
concurrently treated with 3-methyladenine (3-MA), Wortmannin, LY-249004,
Bafilomycin A-1 and Chloroquine, all of which have been shown to inhibit
autophagy in a variety of experimental systems (Meschini et al, 2008; Seglen and
Gordon, 1982; Shacka et al., 2006). However, many of these agents had intrinsic
toxicities making it difficult if not impossible to study the effects of autophagic
inhibition (data not shown).

The late inhibition of H-ATPase pump with

Bafilomycin did seem to partially prevent the acidification of autophagic vesicles
in concurrent treatment with JG-03-14 (Figure 15A). Consequently, studies were
conducted using Bafilomycin A-1 at 10 nM. Figure 15B shows that Bafilomycin
produced a modest protection against the cytotoxic effects of JG-03-14 in both
the MTT absorbance assay as well as the Trypan Blue assay for cell viability.
The fact that protection was relatively modest can be explained by the observed
increase in the amount of apoptotic cells by DAPI staining (Figure 15C).

VIII. Promotion of senescence and lack of proliferative recovery in residual
cells
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In previous studies, we have reported that residual cells that appear to
have survived the drug treatment were in a state of senescence arrest (Arthur et
al. 2007); in some studies, senescence has been succeeded by proliferative
recovery (Elmore et al. 2005). In the current studies, we observe that 95% of the
residual cell populations following treatment with 500 nM JG-03-14 are arrested
in senescence, based on beta-galactosidase staining as well as cell enlargement
and spreading (Figure 16A). Similarly, 91% of the cells treated with 250 nM JG03-14 appeared to be senescent. The induction of senescence could be
observed as early as day 2. Adriamycin was used as a positive control for
senescence.
In order to determine whether the cells had lost self-renewal capacity, drug was
removed after 72 hours and cell number was followed for an additional 17 days.
We failed to detect any evidence of cell re-growth for periods as long as the
study, 20 days total, indicating that the cells had lost all reproductive capacity
(figure 16B).

IX. Relationship between Autophagy and Senescence
A recent review by Young et al. gave insight into the relationship between
autophagy and senescence. Therefore we wanted to investigate whether or not
the inhibition of autophagy in this model would have an effect on senescent cells.
Our studies also revealed that through the inhibition of autophagy, we were able
to attenuate senescence based on beta-galactosidase staining (Figure 15D).
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Analysis of the images showed a 60% reduction in positive staining cells (Figure
15E). Interestingly, this attenuation of senescence did not appear to protect cells
from loss of proliferative capacity (Figure 16B), but does shine light on the
possibility of shared pathways between autophagy and senescence.

This

population of senescent cells was quantified and presented reduction of 95% to
38.7% and 91% to 27% for combination JG-03-14 at 500 nM and 250 nM with
Bafilomycin, respectively (Figure 15E).

This indicates that the combination

treatment is also promoting an alternative mode of cell death, that of apoptosis.

X. Evaluation of JG-03-14 effect on cardiac cell viability

To assess the potential toxicity accompanying the cancer cell killing
effects of JG-03-14, we employed an immortalized in vitro cardiac model, H9c2
cardiomyocytes (Zordoki & El-Kadi, 2007). Combretastatin is a microtubule
poison currently under clinical investigation and has been shown to promote
extensive cardiotoxiticy (Stevenson et al., 2003). Therefore, we wanted to
determine if our compound would have an advantage over the pronounced
toxicities of combretastatin to the heart. Using the MTT dye assay, we found JG03-14 is consistently less toxic than the other microtubule poisons investigated,
combretastatin A-4 and taxol (Figure 17).
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Table 2.
Table 1 – Clonogenic Survival assay following 72h JG-03-14 exposure (% control)
JG-03-14 (250nM)
JG-03-14 (500 nM)
B16F10
4.31 +/- 1.1*
2.7 +/- 0.65*
*
Values represent average colonies formed 2 weeks post 72 hours treatment
JG-03-14
* P= >0.0001 compared to Control group
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Treatment 72h, Day 14

Figure 9. Dose-dependent Effects of JG-03-14 on B16F10 Clonogenic Capacity
B16F10 cells were plated based on previous dose responses. 100 cells for DMSO, JG 10
nM and 500 cells for JG 250 nM and JG 500 nM. Colonies were considered as greater
than 10 cells and lacking the hallmarks of senescence. Assay shown is a representative
experiment done in triplicate and was corrected for plating efficiency. Two identical
replicate experiments were performed for confirmation. Error bars reflect standard
deviations and significant differences from DMSO treatment are indicated by * (P<0.05),
which were assessed by the ANOVA and Tukey/Kramer post-hoc analysis.
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Figure 10: Time dependent loss in cell viability by exposure to JG-03-14. B16F10
cells were continuously exposed to 500nM JG-03-14 and viable cell number was
monitored by trypan blue exclusion over a period of 120 hours. Values shown are from a
representative experiment with triplicate samples for each condition. Studies were
reproduced in two additional replicate experiments. The inset shows the decline in viable
cell number using an expanded Y-axis. Significance differences from DMSO treatment
are indicated by * ( P<0.05) and were assessed by the Student t-test.
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Figure11: Images of B16F10 nuclear integrity of cells exposed to JG-03-14. B16F10
cells were treated with 500nM JG-03-14 for 72 hours. Apoptosis and mitotic catastrophe
were evaluated based on morphology by DAPI staining (A) and Hoechst (B) (nuclear
fragmentation and bi-nucleated cells with micronuclei, respectively).
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Figure 12: Cell Cycle Distribution of B16F10 cells exposed to JG-03-14. B16F10 cells
were treated continuously with various microtubule poisons. Both supernantant and
adherant cells were collected and analyzed using propidium iodide single cell analysis
after both 24 hours and 72 hours.
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Figure 13. Assessment of autophagy in B16F10 cells exposed to JG-03-14 B16F10
cells were treated with Vehicle, 500nM JG-03-14, and 100 nM Combretastatin A-4
continuously and autophagy was assessed based on acridine orange staining 400X ( A)
and monodansylcadaverine 200X (B) staining at 72 hours.
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Figure 14: Confirmation of autophagy in B16F10 cells exposed to JG-03-14
Autophagy was confirmed using electron microscopy visualization. B16F10 cells were
treated for 72 hours continuously prior to fixation and staining. Scale-bars indicate
magnification comparisons for cell enlargement.
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Figure 15. The effect of Bafilomycin on B16F10 response to JG-03-14 The B16F10
cells were exposed to either JG-03-14 250 nM or 500 nM and Bafilomycin 10 nM or in
combination. Adriamycin and Taxol used as positive controls. Acridine orange staining
was used as a measure of autophagy (200X) (A), as well as its protective effects on cell
viability using trypan blue and MTT absorbance assays (B). Also shown is the effect the
combination had on nuclear integrity as seen by DAPI (400X) (C), attenuating effects on
senescence (200X) (D) and quantified blue positive staining (E). Viability assays are two
replicate experiments combined each done in triplicate.
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Figure 16: Senescence and destruction of proliferative recovery for B16F10 cells
exposed to JG-03-14 B16F10 cells were treated with 500nM JG-03-14 for 72 hours,
drug was removed and replaced with drug free medium. Medium was replaced every 3
days. Beta-galactosidase staining (A) and lack of proliferative recovery (B) is displayed
as assessed using trypan blue trypan blue. Blue Diamonds (JG-03-14 500 nM), Maroon
Triangles (JG + Bafilomycin 10 nM). Significant differences from DMSO treatment day
3 for both JG alone and Combination are indicated by * (P<0.05) and were assessed by
the two-way ANOVA and Fisher’s PLSD post-hoc.
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Figure 17: Effects of microtubule poisons Taxol, Combretastatin A-4 and JG-03-14 on
H9c2 rat embryonic cardiomyocytes. H9c2 cells were treated dose dependently with nano
molar concentrations of JG-03-14, Taxol and Combretastatin A-4. MTT absorbance assay shows
a concentration dependent decline in viable cell number. Shown is a representative experiment
performed with samples in triplicate. An identical replicate experiment was performed to
confirm results. Significant differences from DMSO treatment day 3 for both JG alone and
Combination are indicated by * (P<0.05) and were assessed by the one-way ANOVA and
Fisher’s PLSD post-hoc.
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CHAPTER 4 Discussions

The American Cancer Society estimates that in 2010 there will be over 1 million
new cancer patients (American Cancer Society, 2010).

These astronomical

numbers also contribute to 1 in every 4 deaths, which equal about 1500 lives per
day. Of those, colon cancer, breast cancer and melanoma are some of the most
deadly malignancies when not detected early. The current microtubule targeting
agents for metastatic disease are not very effective (Fojo et al., 2007; Sampath el
al., 2006; Delaunoit et al., 2005). Even when the drugs are effective, they also
have numerous debilitating toxicities. Cardiotoxicity, peripheral neuropathy and
the development of drug resistance are a few of the major drawbacks associated
with current cancer chemotherapy (American Cancer Society, 2009). Previous
studies from our lab have shown the effects of JG-03-14 on MDA-MB-231, MCF7 and MCF-7/E6 breast tumor cells, of which all appear to be sensitive to JG-0314 through either apoptosis or autophagy (Arthur et al., 2007).
The primary findings of our studies are that both HCT-116 colon
carcinoma cells and a B16F10 melanoma cell line are sensitive to the novel
microtubule poison, JG-03-14. The initial response to treatment is cell death,
primarily through autophagy. A residual surviving cell population is in a state of
senescence, which appears to be irreversible, even when drug is removed as
shown by the lack of proliferative recovery. Clonogenic survival studies indicate
that at a concentration of 500 nM there is an approximate 98.5% reduction in
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survival of HCT-116 cells and a 97.3% reduction in survival of the melanoma
cells. The effects on clonogenic survival are markedly similar while the time
course studies of cell killing demonstrate dramatic differences between the two
cell lines. One hypothesis for the overall decreased sensitivity of the B16F10
cells is the high amount of what appears to be a basal autophagy, which has
been mentioned by other groups (Tormo et al, 2009).

This basal level of

autophagy may stage the cells to enter into senescence at a more accelerated
rate as opposed to entering autophagic cell death, similar to what has been
reported in response to high concentrations of adriamycin (Vicencio et al., 2008;
Di et al, 2006, 2009).

Cell Death by Autophagy
Autophagy is a process that involves the formation of double membrane acidic
vesicles around cellular organelles such as mitochondrial or endoplasmic
reticulum; the autophagosomes then fuse with lysosomes that provide the
enzymes for degradation of the autophagolysosomal content (Dunn, 1994). In
control acridine orange-stained cells, the cytoplasm and nucleus fluoresce bright
green and dim red respectfully, whereas in cells undergoing autophagy, the
acidic compartments fluoresce bright orange (Paglin et al., 2001).

Our

observations of autophagic vacuoles in JG-03-14 treated cells stained with
acridine orange indicate the presence of autophagolysosomes. The untreated
controls in both HCT and B16 cells generally show a single condensed large
vacuole situated near the nucleus. The literature does indicate that in some
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cases autophagy is an alternative mode of cell death when apoptosis is defective
due to p53 mutations or its inhibition (Kim et al., 2006; Yu et al., 2006). However,
since our cells are not p53 deficient, this explanation would not apply. Other
work has shown that autophagy may contribute to the tumor suppressive function
of p53, (Jin 2005; Zeng et al., 2007) and that p53 may be involved in the
induction of autophagy (Tasdemir et al., 2008; Levine et al., 2008).

Autophagy was also confirmed using monodansylcadaverine staining in the both
cell lines in response to JG-03-14. MDC is sometimes considered to be a more
reliable indicator of autophagic vacuole formation because of its interaction with
the autophagic membrane and not just the acidic compartment of the
autophagosome (Biederbick et al., 1995). Transmission electron microscopy
further substantiated the autophagic vesicle engulfing organelles and the
autophagic machinery being executed in both the colon and melanoma cell lines.

A protein associated with autophagy is microtubule associated protein light chain
3. LC3-II is a proteolytic product of LC3-I that is required for the formation of
autophagosomes and is a known marker of autophagy (Asanuma et al., 2003).
Prior to the induction of autophagy, RFP-LC3 shows a diffuse localization of red
within the cytoplasm, whereas once autophagy is induced, the cleaved protein
will associate with the membrane of the autophagic vesicle.

This punctuate

pattern is indicative of the autophagic process (Zeng et al., 2007). Our RFPLC3-II punctuate pattern within the cytoplasm further supports the conclusion of
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autophagic activity after incubation with JG-03-14 in the HCT-116 cells (Niemann
et al., 2000). We also attempted to transfect the B16F10 cells. The RFP-LC3
was successfully transferred and visualized, but we were not able to maintain the
stability of the fluorescent protein. Consequently, we were unable to evaluate the
stable expression model of the fluorescent protein in this cell line.

Autophagic Flux

Another protein that has provided experimental evidence for autophagy is
p62/SQSTM1 (Moscat et al., 2009). P62 is a ubiquitous scaffold protein that is
associated with membrane formation for autophagosomes. During autophagic
flux, the double membrane vesicles will fuse with the lysosome and p62 will be
degraded (Bjørkøy et al, 2009). Our studies demonstrate autophagic flux in the
HCT-116 cells when treated with JG-03-14. Here again, the B16F10 cells did not
show evidence of p62 protein expression across all treatments or controls,
possibly due to the basal level of autophagy resulting in undetectable levels in
our assays. We hope to use an odyssey bioluminescence assay in the future to
amplify the protein expression and confirm if our prediction of autophagic flux is
correct. In HCT-116 cells, we do show a decline in p62 levels after 48 hours of
incubation with JG-03-14 as well as partial restoration when cells are treated
concurrently with the lysomotropic inhibitor chloroquine.

Inhibition of Autophagy to validate a mode of cell death
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In order to further confirm our findings that the primary mechanism of cell killing
induced by JG-03-14 is autophagy; we utilized pharmacological agents to inhibit
the autophagic process. Chloroquine and Bafilomycin A-1 are lysomotropic and
H+-ATPase inhibitors, respectively (Shintani et al., 2004; Yamamoto et al., 1998).
These compounds have been shown to inhibit the fusion of the autophagosome
and the lysosome, which in turn inhibits the last step of the autophagic process
(Shintani et al., 2004). In our studies, we found that the inhibitors generated
somewhat ambiguous outcomes. The combination of autophagic inhibitors with
JG-03-14 seemed to have a partially protective response against cell killing. As
the autophagic process was being inhibited, the final mechanism of cell death
appeared to be converted to the apoptotic machinery. This blockade of
autophagy could be visualized using MDC, acridine orange staining while
apoptosis was detected by DAPI staining, and the TUNEL assay. The blockade
to autophagy in HCT-116 cells was confirmed by restoration of p62 levels while
apoptosis was confirmed by FACS analysis. These effects observed with JG-0314 and the use of concurrent autophagic inhibitors redirecting the cell to
apoptosis is similar to what others have reported with tamoxifen (Amaravardi et
al., 2007).

Absence of apoptosis as the primary response to JG-03-14.
It was of particular interest that JG-03-14 failed to promote extensive
apoptosis in either the HCT-116 cells or the B16F10 melanoma cells. This may
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be related to the fact that both cell lines are wild type in p53 and previous work in
MCF-7 cells demonstrated primarily autophagy induced by JG-03-14 in this p53
wild type cell line (Arthur et al., 2007). There appears to be an ambiguous role of
p53 with regards to autophagy. A recent paper described how both the over
expression and silencing of p53 can induce autophagy (Tasdemir et al., 2008).
This may correlate to the dual role of autophagy being cytotoxic and
cytoprotective (Baehrecke, 2005).

The induction of p53 may also be cell

protective if a DNA damaging agent activates the cell’s DNA damage response to
arrest the cells with intentions of DNA repair and proliferation (Tasdemir et al.,
2008). p53 induction could also be a mechanism whereby the cell has endured
DNA damage and is poised to undergo intrinsic apoptosis as a means of cellular
suicide (Prabhudesai et al., 2007). With JG-03-14 treatments, we did not detect
induction of p53. DAPI staining studies and cell cycle analyses indicated that
both taxol and combretastatin A-4 are killing cells through a different mechanism.
Taxol has been shown to induce G1 arrest and apoptosis whereas
combretastatin A-4 may drive cells into the apoptotic pathway after being prestaged by mitotic catastrophe (Wagenknecht et al., 1998; Blajeski et al., 2001;
Vakifahmetoglu et al., 2008). Some microtubule poisons have shown similar
arrest in G2/M, but are markedly different from JG-03-14 in that they can activate
p53 to execute apoptosis (Sayed et al, 2001). Since the models tested with JG03-14 all show minimal induction of apoptosis in a system that contains wild-type
p53, this is consistent with the idea that another mode of cell death (autophagy)
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is occurring. These findings could represent a unique advantage for the use of
this drug in treatment of apoptosis resistant tumors.

Cell Cycle Arrest in Response to JG-03-14
In studies of drug effects on cell cycle distribution, we observed that the
cells arrested primarily in the G2/M phase of the cell cycle. This is consistent with
the effects of other microtubule depolymerizers (Azeddine et al., 1998; Quan et
al., 2007). These observations suggest that JG-03-14 failed to activate the G1
cell cycle checkpoint; in fact, Western blotting indicated that JG-03-14 failed to
induce either p53 or p21 (data not shown). Although other microtubule poisons
have been shown to arrest cells in G2/M and conclude with promotion of
apoptosis as a means for cell killing (Zhu et al, 2010), this was clearly not the
case for JG-03-14.

In JG-03-14 treated cells, autophagy does not appear to

damage the nuclear contents based on DAPI staining, the TUNEL assay and
non-induction of p53. We therefore believe the population of cells arrested in
G2/M phase may show continual depolymerizing activity to destroy cellular
contents until the possibility of recovery has been bypassed.
We also observed a hyperdiploid population after treatment of either
B16F10 cells or HCT-116 cells with JG-03-14, likely due to the ability of cancer
cells to undergo mitotic slippage out of the G2/M arrest and re-replicate their
DNA in the absence of cytokinesis (Gross et al., 1995).

However, this response

was unexpected in these p53 wild type cells, since endoreduplication is generally
associated with the absence of functional p53 to induce G1 arrest and to sustain
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arrest in G2 (Aylon et al, 2006); functional p53 generally promotes arrest in
G0/G1 to prevent post-mitotic slippage (Stewart et al., 1999; Elhajouji et al,
1998). In fact, our previous studies showed that MDA-MB-231 mutant p53 breast
tumor cells, but not p53 wild type MCF-7 cells, undergo endoreduplication (Arthur
et al, 2007). The ability of the wild type p53 HCT-116 colon cancer cells as well
as the B16F10 melanoma cells to undergo mitotic slippage indicates that tumor
cells can become polyploid even in cells with functional p53, presumably
because checkpoint signaling downstream of p53 is attenuated.

Absence of mitotic catastrophe in response to JG-03-14
The fact that there was evidence of polyploidy indicated that the cells were
attempting to undergo cytokinesis following the G2/M arrest. One possible
outcome of aberrant mitosis would be mitotic catastrophe (Vakifahmetoglu et al.,
2008). Cell death by mitotic catastrophe is characterized by the formation of
nuclear envelopes around individual clusters of missegregated chromosomes.
These are formed during the misguided or early entry into mitosis with aberrant
cytokinesis. This then culminates with the accumulation of micronuclei and
appears similar to necrotic cell death. Mitotic catastrophe remains to be fully
defined biochemically but the mode of cell killing is also thought to be pre-stage
to induction of apoptosis (Vakifahmetoglu et al., 2008). Caspase 3 and PARP
cleavage as well as mitotic catastrophe have been seen in response to
combretastatin (Vitale et al., 2006). Using Hoechst stain, we failed to detect
evidence of mitotic catastrophe following treatment with JG-03-14.
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Senescence and proliferative recovery
In our studies, we showed that not only did the JG-03-14 compound arrest the
cells in the G2/M stage, but that JG-03-14 also produced a massive amount of
cell killing within this same population of cells possibly following the arrest. After
treatment, the cell population was monitored to determine if the surviving cells
ultimately overcame the initial treatment and would regain proliferative capacity
after the drug was removed.

Our studies in both cell lines indicated that

proliferative recovery was entirely disrupted. The cells were incapable of
replication as far out as 17 days after replacement of drug medium with drug-free
medium.
A large percent of the cells that were not killed entered into a senescent
phase based on enlargement, flattening and lack of colony formation.

Beta-

galactosidase staining confirmed that this non-proliferating population was in fact
senescent (Itahana et al., 2007; Arthur et al., 2007). Therefore, the variations in
cell killing observed between the B16F10 cells and the HCT-116 may be due to
the basal levels of autophagy (Tormo et al., 2009).

The basal levels of

autophagy in the B16F10 melanoma cells seen may pre-stage the melanoma
cells to enter into senescence instead of massive amounts of autophagic cell
death seen in the HCT-116.
Toxicity studies in cell culture and in vivo
Since microtubule poisons such as taxol and combretastatin have a
number of undesirable dose limiting toxicities, including peripheral neuropathy
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and cardiotoxicity among others (Scuteri et al., 2006; Stevenson et al., 2003), it
was of importance to assess the influence of JG-03-14 on heart cells and to
perform behavioral studies relating to neuropathy as an indication of its potential
to cause neuropathic injury. In a preliminary dose response studies and using
comparable doses of taxol and combretastatin, JG-03-14 appears to be least
toxic of the three microtubule poisons. However, the relevance of this study to
cardiac toxicity is somewhat questionable since the h9c2 cell line, unlike the
heart, is a replicating model. Another microtubule poison, colchicine, is not used
in the clinic because of associated peripheral neuropathy and being a substrate
for the p-glycoprotein pump (Kuncl et al., 1987). This pump is one mechanism
by which cancer cells can become resistant to chemotherapy and JG-03-14 has
been shown not to be a substrate (Mooberry et al., 2007). Preliminary in vivo
data also show there were no behavioral toxicity effects at doses of 100mg/kg
and 200mg/kg. These findings together with studies indicating minimal toxicity in
vivo suggest that JG-03-14 could be an improvement over the current clinical
therapies.

Future Studies
Our studies have confronted a number of problems when using
pharmacological inhibitors of autophagy. Chloroquine alone proved to be toxic in
the B16F10 cells. Other autophagic inhibitors that target the PI3-K pathway such
as Wortmannin, LY-249002 and 3-methyl adenine prove to be toxic at
concentrations necessary to show autophagic inhibition. We therefore utilized
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the late stage pharmacological inhibitors of autophagy at very low, non-toxic
concentrations. An important study would be to use an inhibitor of caspase
cleavage and possibly the induction of apoptosis. A pan-caspase inhibitor such
as z-VAD in combination with JG-03-14 and a low dose autophagic inhibitor may
divulge some mechanisms of cell response and possibly alter sensitivity (Yu et
al., 2003). In order to fully understand the process, we also want to silence
genes (atg’s) as well as Beclin-1 (Suzuki et al., 2007; Yue et al., 2003). This
approach would determine the reliance of JG-03-14 on autophagy proteins for
cell killing. Since JG-03-14 has also been shown to induce apoptosis in other
cell lines, the mechanism of cell killing may be cell type dependent (Arthur et al.,
2007; Mooberry et al., 2007).
Knowledge of the precise signaling pathways for autophagic death
induced by JG-03-14 remain to be defined, with a focus on mTOR and ER stress
signaling. The literature suggests that autophagy could be a consequence of
selective protein degradation, specifically catalase degradation causing an
accumulation of ROS or degradation of other essential proteins that would
eventually kill the cells (Yu et al., 2006; Onodera and Ohsumi, 2004). In concert
with further defining the mechanism of action of JG-03-14, we would also like to
see if it is as efficacious in vivo as it is in vitro. This would help define if the
effects in cell culture are translational and could be applicable to the clinic. It
would be of particular interest to test JG-03-14 in an immunocompetent mouse to
see if some of the autophagic and senescent effects were to be cleared by the
immune system.
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Overview

In summary, these studies lead to a number of conclusions. Colchicine is
not used in the clinic because it has been shown to be a substrate for the pglycoprotein MDR pump as well as the glutathione S-transferase found in
resistant cells (Ruiz-Gomez et al, 2000). Colchicine has also been shown to
suppress bone marrow function (Liu et al, 2008; Harris et al, 2000) and to be
highly toxic. In contrast, JG-03-14 had been determined not to be a substrate for
the p-glycoprotein pump and to be relatively non-toxic (Mooberry et al, 2007).

Different microtubule targeting agents can cause either a G1 or G2 arrest,
and the arrest may be p53-dependent or p53 independent. The fact that JG-0314 induced a G2 arrest and there was no induction of p53 suggests that JG-0314 may be less reliant on p53. This is significant in that cancers that acquire
resistance via evasion of the p53-dependent mechanism may be sensitive to the
alternative mechanism of cell cycle arrest that could ultimately lead to an
alternative death signal. Since adjuvant radiotherapy is often used in preventing
colon cancer recurrence, a G2/M block induced by JG-03-14 could stage the
colon cancer cells for radiosensitization (Zheng, 2008; Jorgensen et al, 2007).

The results presented above have potentially important implications for
JG-03-14 as a clinically effective agent due to its ability to promote autophagy.
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By targeting autophagic induction of tumor regression, JG-03-14 may be able to
bypass colon cancer and melanoma’s high metastatic rate which typically
accompanies resistance to apoptosis.

Drugs that target microtubules are important in cancer therapeutics, some
of which are among the most effective in treating childhood and adult tumors.
Though drugs such as combretastatin A-4 and 2ME2 bind to the same site on
tubulin, they have different effects on tumor vasculature. 2ME2 has antiangiogenic actions while combretastatin A-4 has anti-vascular activities that lead
to a rapid collapse in tumor vasculature (Mooberry et al., 2003; Griggs et al.,
2001).

The ability of JG-03-14 to bind to tubulin and its action as a

depolymerizer suggest its potential effects on tumor vasculature The maturation
of angioblasts into endothelial cells is crucial for vascular tubule formation (Tozer
et al, 1999). JG-03-14 at 100 nM concentration was able to inhibit endothelial
cells tube formation, attachment, and migration, which indicates that JG-03-14
may have potential as a chemotherapeutic drug for cancer (Dalyot-Herman et al,
2009).
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